Drugs / Standard Dose Quadrivalent Influenza Vaccine
Standard Dose Quadrivalent Influenza Vaccine
Trials 0
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05624606 Comparator | Nov 2022 → Mar 2024 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 1/2 | NCT03233217 Comparator | Sep → Nov 2017 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04537234 Comparator | Nov 2020 → Feb 2021 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT03965195 Comparator | Jul 2019 → Aug 2023 | influenza | Insight Therapeutics, LLC | Unknown | No outcome recorded |
| Phase 4 | NCT02787044 Comparator | Aug 2016 → May 2020 | heart failure, myocardial infarction | Brigham and Women's Hospital | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Standard-Dose Quadrivalent Influenza Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04537234 ↗ |
| Known as | IIV4 | “Nursing homes were cluster randomized to vaccinate all residents with recombinant quadrivalent influenza vaccine (RIV4) or standard egg-based quadrivalent inactivated influenza...” PMID 39745702 ↗ Jan 2025 |
| Known as | QIV-SD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05624606 ↗ |
| Modality | Vaccine | “standard-dose quadrivalent inactivated influenza vaccine” PMID 33275134 ↗ Jan 2021 |
| Route | Subcutaneous | “QIV-SD by SC route” NCT03233217 ↗ |